Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agenus Inc (NQ: AGEN )

1.030 UNCHANGED
Streaming Delayed Price Updated: 9:58 AM EDT, Oct 4, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Agenus Inc

< Previous 1 2 Next >
Agenus to Present Botensilimab Data at Late-Breaking Oral Session at ASCO-GI
From Agenus Inc.
Via GlobeNewswire
Agenus Data at CTOS 2022 Highlight Durable Clinical Responses of Botensilimab / Balstilimab Combination in Advanced Sarcoma
From Agenus Inc.
Via GlobeNewswire
Agenus to Participate at 5th Annual Evercore ISI HealthCONx Conference
From Agenus Inc.
Via GlobeNewswire
Agenus Data at SITC 2022 Highlight Durable Responses of Botensilimab / Balstilimab Combination in Nine Different Treatment-Resistant Cancers
From Agenus Inc.
Via GlobeNewswire
Agenus Provides Corporate Update and Third Quarter 2022 Financial Report
From Agenus Inc.
Via GlobeNewswire
Agenus to Provide Corporate Update and Third Quarter 2022 Financial Report
From Agenus Inc.
Via GlobeNewswire
GSK’s older adult RSV vaccine candidate, containing Agenus’ QS-21 STIMULON™, shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial
From Agenus Inc.
Via GlobeNewswire
VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients
From Agenus Inc.
Via GlobeNewswire
Agenus to Host “The Road Taken” R&D Event on November 12, 2022
From Agenus Inc.
Via GlobeNewswire
Agenus to Present Botensilimab Data at a Plenary Session of the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
From Agenus Inc.
Via GlobeNewswire
Agenus to Provide Corporate Update and Second Quarter 2022 Financial Report
Conference Call on Tuesday, August 9, 2022 at 8:30 a.m. ET 
From Agenus Inc.
Via GlobeNewswire
Why ‘Killer’ T Cells Could Boost COVID Immunity In Face Of New Variants
Via FinancialNewsMedia
Exposures COVID-19
Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody Program
From Bristol-Myers Squibb
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.